Taysha gene therapies announces first pediatric patient dosed with tsha-102 in reveal phase 1/2 pediatric trial in rett syndrome

Initiation of reveal pediatric trial in the u.s. broadens the clinical evaluation of tsha-102 to female patients 5-8 years old with stage three rett syndrome
TSHA Ratings Summary
TSHA Quant Ranking